SEC Form 4 · accession 0001209191-17-051052
Conatus Pharmaceuticals Inc. · CNAT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith W Marshall
Officer — EVP, COO & CFO
Period of report
Aug 31, 2017
Accepted (ET)
Sep 1, 2017 · 4:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001383701
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $5.74 | Aug 31, 2017 | A | 525,000 | A | — | Aug 30, 2027 | Common Stock | 525,000 | 525,000 | D |
Explanation of responses
- F1The option was granted on August 31, 2017. Twenty-five percent (25%) of the total number of shares of common stock subject to the option will vest on August 31, 2018, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Remarks
Represents an inducement award of stock options to the Reporting Person in connection the commencement of the Reporting Person's employment with the Issuer.